IL1B and Hepatomegaly: This study identified significant signals of hepatocellular injury and hepatomegaly in anakinra-associated AEs, as well as hepatomegaly and transaminase elevation in canakinumab-associated AEs, thus confirming the association between IL-1 blockers and liver injury.